Novel Anti-Thrush Treatment Reaches Phase II
A novel antifungal agent developed by Viamet Pharmaceuticals has just entered Phase II trials, bringing it one step closer to approval.
The investigational product, called VT-1161, is now going to be investigated for its safety and efficacy in the treatment of vulvovaginal candidiasis (VVC). The drug is novel in its approach as it selectively inhibits the fungus in the area . Previous trials in the US have shown good safety, tolerability and pharmacokinetics.
Thrush is often seen as a minor issue and 75% women suffer form it at some point in their lives. However, 5-8% of women suffer from stubborn thrush, called recurrent vulvovaginal candidiasis (RVVC). There are currently no approved agents to treat RVVC, meaning women get left on long courses of antifungals which destroy the natural fauna in the area. This can lead to greater infection and so a constant spiral of medication and reinfection.
Over-the-counter treatments are no match for RVVC so this treatment is very important as it focuses on a specific fungus rather than a blanket approach affecting the whole area.
To read more, click here:
Image of the thrush organism is provided courtesy of http://quizlet.com